Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1930 1
1951 1
1952 1
1957 2
1958 1
1959 3
1960 3
1961 4
1962 2
1963 2
1964 1
1965 5
1966 2
1967 5
1968 6
1969 3
1970 7
1971 7
1972 6
1973 6
1974 5
1975 8
1976 6
1977 4
1979 1
1980 1
1982 1
1983 1
1985 1
1986 4
1987 2
1988 5
1989 1
1990 10
1991 3
1992 2
1995 2
1996 1
1999 1
2000 1
2002 1
2004 2
2005 4
2006 2
2007 3
2008 1
2009 3
2010 1
2011 5
2012 7
2013 6
2014 10
2015 7
2016 3
2017 5
2018 8
2019 10
2020 5
2021 10
2022 5
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

217 results

Results by year

Filters applied: . Clear all
Page 1
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI–IM-UNITI Study Group. Feagan BG, et al. N Engl J Med. 2016 Nov 17;375(20):1946-1960. doi: 10.1056/NEJMoa1602773. N Engl J Med. 2016. PMID: 27959607 Free article. Clinical Trial.
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, Arrese M, Corpechot C, Francque SM, Heneghan MA, Invernizzi P, Jones D, Kruger FC, Lawitz E, Mayo MJ, Shiffman ML, Swain MG, Valera JM, Vargas V, Vierling JM, Villamil A, Addy C, Dietrich J, Germain JM, Mazain S, Rafailovic D, Taddé B, Miller B, Shu J, Zein CO, Schattenberg JM; ELATIVE Study Investigators’ Group; ELATIVE Study Investigators' Group. Kowdley KV, et al. Among authors: kruger fc. N Engl J Med. 2024 Feb 29;390(9):795-805. doi: 10.1056/NEJMoa2306185. Epub 2023 Nov 13. N Engl J Med. 2024. PMID: 37962077 Clinical Trial.
Structural and Functional View of Polypharmacology.
Moya-García A, Adeyelu T, Kruger FA, Dawson NL, Lees JG, Overington JP, Orengo C, Ranea JAG. Moya-García A, et al. Among authors: kruger fa. Sci Rep. 2017 Aug 31;7(1):10102. doi: 10.1038/s41598-017-10012-x. Sci Rep. 2017. PMID: 28860623 Free PMC article.
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
Danese S, Colombel JF, Lukas M, Gisbert JP, D'Haens G, Hayee B, Panaccione R, Kim HS, Reinisch W, Tyrrell H, Oh YS, Tole S, Chai A, Chamberlain-James K, Tang MT, Schreiber S; GARDENIA Study Group. Danese S, et al. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):118-127. doi: 10.1016/S2468-1253(21)00294-6. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798038 Free article. Clinical Trial.
217 results